Cost-effectiveness of prostate health index for prostate cancer detection

BJU International

Volumn 110, Issue 3, 2012, Pages 353-362

  Nichol, Michael B ^a,b   Wu, Joanne ^a   Huang, Joice ^c   DenHam, Dwight ^d   Frencher, Stanley K ^e   Jacobsen, Steven J ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b School of Policy Planning and Development   (United States)

^c AMGEN INC   (United States)

^d BECKMAN COULTER INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

cost effectiveness analysis; free PSA; prostate health index (phi); prostate specific antigen (PSA); PSA precursor form 2 proPSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BECKMAN COULTER PROSTATE HEALTH INDEX; CALCULATION; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; SENSITIVITY ANALYSIS;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84863719857     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10751.x     Document Type: Article

References (49)

1. Stark JR, Mucci L, Rothman KJ, Adami HO,. Screening for prostate cancer remains controversial. BMJ 2009; 339: b3601
2. Greene KL, Albertsen PC, Babaian RJ, et al,. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-41
3. Wolf A, Wender R, Etzioni R, et al,. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98
4. Andriole GL, Crawford ED, Grubb RL 3rd, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
5. Schröder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
6. Roobol MJ, Kerkhof M, Schröder FH, et al,. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-91
7. Wever EM, Draisma G, Heijnsdijk EA, et al,. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst 2010; 102: 352-5
8. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level â4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
9. Thompson IM, Ankerst DP,. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853-8 (Pubitemid 46999868)
10. Kaplan DJ, Boorjian SA, Ruth K, et al,. Evaluation of the prostate cancer prevention trial risk calculator in a high-risk screening population. BJU Int 2010; 105: 334-7
11. Catalona WJ, Bartsch G, Rittenhouse HG, et al,. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate specific antigen. J Urol 2004; 171 (6 Pt 1): 2239-44 (Pubitemid 38625443)
12. Holmberg L, Bill-Axelson A, Helgesen F, et al,. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9 (Pubitemid 34988336)
13. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101 (Pubitemid 40617061)
14. Wilt TJ,. Prostate carcinoma practice patterns-what do they tell us about the diagnosis, treatment, and outcomes of patients with prostate carcinoma? Cancer 2000; 88: 1277-81 (Pubitemid 30155161)
15. Potosky AL, Davis WW, Hoffman RM, et al,. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358-67 (Pubitemid 39406169)
16. McNaughton-Collins M, Fowler FJ Jr, Caubet JF, et al,. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004; 117: 719-25 (Pubitemid 39482524)
17. Brawley OW, Ankerst DP, Thompson IM,. Screening for prostate cancer. CA Cancer J Clin 2009; 59: 264-73
18. Jansen FH, van Schaik RHN, Kurstjens J, et al,. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-7
19. Le BV, Griffin CR, Loeb S, et al,. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-9
20. Catalona WJ, Partin A, Sanda MG, et al,. A multi-center study of [-2]pro-prostate-specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range. J Urol 2011; 185: 1650-5
21. Nichol MB, Wu J, An JJ, et al,. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis 2011; 14: 253-61
22. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E,. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003; 169: 1720-3 (Pubitemid 36443480)
23. van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH,. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95: 1462-6 (Pubitemid 37279331)
24. Hoedemaeker RF, van der Kwast TH, Boer R, et al,. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001; 93: 1153-8 (Pubitemid 32780967)
25. Postma R, Roobol M, Schröder FH, van der Kwast TH,. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004; 100: 968-75 (Pubitemid 38222857)
26. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG,. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 1397-405 (Pubitemid 38366842)
27. Schröder FH, Bangma CH, Roobol MJ,. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/mL? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008; 53: 901-8
28. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Available at:. Accessed 20 July 2010
29. Lim L, Sherin K, ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men. ACPM position statement on preventive practice. Am J Prev Med 2008; 34: 164-70
30. University of Michigan Health System (UMHS). Adult Preventive Health Care: Cancer Screening. Ann Arbor, MI: University of Michigan Health System, 2004: 12
31. National Coverage Determination (NCD) for prostate cancer screening tests. Available at:. Accessed 23 October 2011
32. United States Preventive Services Task Force (USPSTF). Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-91
33. Lacher DA, Thompson TD, Hughes JP, Saraiya M,. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04. Adv Data 2006; 379: 1-12
34. Andriole GL, Levin DL, Crawford ED, et al,. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433-8 (Pubitemid 40528606)
35. Hayes JH, Ollendorf DA, Pearson SD, et al,. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-80
36. Arias E,. United States life tables, 2004. Natl Vital Stat Rep 2007; 56: 1-39
37. Stokes ME, Black L, Benedict A, et al,. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010; 13: 278-84
38. Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD,. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007; 27: 288-98 (Pubitemid 46801746)
39. Ghani KR, Dundas D, Patel U,. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004; 94: 1014-20 (Pubitemid 39577086)
40. Lee SH, Chen SM, Ho CR, Chang PL, Chen CL, Tsui KH,. Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with prostate cancer. Chang Gung Med J 2009; 32: 623-7
41. McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR,. False-positive cancer screens and health-related quality of life. Cancer Nurs 2004; 27: 347-52 (Pubitemid 39359233)
42. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS,. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272: 773-80 (Pubitemid 24275689)
43. Stinnett AA, Mullahy J,. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl.): S68-80 (Pubitemid 28175944)
44. Barton GR, Briggs AH, Fenwick EA,. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008; 11: 886-97
45. Knudsen AB, McMahon PM, Gazelle GS,. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007; 25: 203-8 (Pubitemid 350003035)
46. Catalona WJ, Smith DS, Ratliff TL, et al,. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
47. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA,. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863-9 (Pubitemid 26198913)
48. Thompson IM, Ankerst DP, Chi C, et al,. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34 (Pubitemid 43898816)
49. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM,. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005; 43: 347-55 (Pubitemid 40515624)